Cargando…

Immunotherapy using slow-cycling tumor cells prolonged overall survival of tumor-bearing mice

BACKGROUND: Despite considerable progress in the development of anticancer therapies, there is still a high mortality rate caused by cancer relapse and metastasis. Dormant or slow-cycling residual tumor cells are thought to be a source of tumor relapse and metastasis, and are therefore an obstacle t...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Qing, Zhong, Yong, Wu, Fan, Zhou, Chunxia, Wang, Dongmei, Ma, Wenbo, Zhang, Youhui, Zhang, Shuren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3568736/
https://www.ncbi.nlm.nih.gov/pubmed/23270473
http://dx.doi.org/10.1186/1741-7015-10-172
_version_ 1782258808864636928
author Sun, Qing
Zhong, Yong
Wu, Fan
Zhou, Chunxia
Wang, Dongmei
Ma, Wenbo
Zhang, Youhui
Zhang, Shuren
author_facet Sun, Qing
Zhong, Yong
Wu, Fan
Zhou, Chunxia
Wang, Dongmei
Ma, Wenbo
Zhang, Youhui
Zhang, Shuren
author_sort Sun, Qing
collection PubMed
description BACKGROUND: Despite considerable progress in the development of anticancer therapies, there is still a high mortality rate caused by cancer relapse and metastasis. Dormant or slow-cycling residual tumor cells are thought to be a source of tumor relapse and metastasis, and are therefore an obstacle to therapy. In this study, we assessed the drug resistance of tumor cells in mice, and investigated whether vaccination could promote survival. METHODS: The mouse colon carcinoma cell line CT-26 was treated with 5-fluorouracil to assess its sensitivity to drug treatment. Mice with colon tumors were immunized with inactivated slow-cycling CT-26 cells to estimate the efficacy of this vaccine. RESULTS: We identified a small population of slow-cycling tumor cells in the mouse colon carcinoma CT-26 cell line, which was resistant to conventional chemotherapy. To inhibit tumor recurrence and metastasis more effectively, treatments that selectively target the slow-cycling tumor cells should be developed to complement conventional therapies. We found that drug-treated, slow-cycling tumor cells induced a more intense immune response in vitro. Moreover, vaccination with inactivated slow-cycling tumor cells caused a reduction in tumor volume and prolonged the overall survival of tumor-bearing mice. CONCLUSIONS: These findings suggest that targeting of slow-cycling tumor cells application using immunotherapy is a possible treatment to complement traditional antitumor therapy.
format Online
Article
Text
id pubmed-3568736
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35687362013-02-12 Immunotherapy using slow-cycling tumor cells prolonged overall survival of tumor-bearing mice Sun, Qing Zhong, Yong Wu, Fan Zhou, Chunxia Wang, Dongmei Ma, Wenbo Zhang, Youhui Zhang, Shuren BMC Med Research Article BACKGROUND: Despite considerable progress in the development of anticancer therapies, there is still a high mortality rate caused by cancer relapse and metastasis. Dormant or slow-cycling residual tumor cells are thought to be a source of tumor relapse and metastasis, and are therefore an obstacle to therapy. In this study, we assessed the drug resistance of tumor cells in mice, and investigated whether vaccination could promote survival. METHODS: The mouse colon carcinoma cell line CT-26 was treated with 5-fluorouracil to assess its sensitivity to drug treatment. Mice with colon tumors were immunized with inactivated slow-cycling CT-26 cells to estimate the efficacy of this vaccine. RESULTS: We identified a small population of slow-cycling tumor cells in the mouse colon carcinoma CT-26 cell line, which was resistant to conventional chemotherapy. To inhibit tumor recurrence and metastasis more effectively, treatments that selectively target the slow-cycling tumor cells should be developed to complement conventional therapies. We found that drug-treated, slow-cycling tumor cells induced a more intense immune response in vitro. Moreover, vaccination with inactivated slow-cycling tumor cells caused a reduction in tumor volume and prolonged the overall survival of tumor-bearing mice. CONCLUSIONS: These findings suggest that targeting of slow-cycling tumor cells application using immunotherapy is a possible treatment to complement traditional antitumor therapy. BioMed Central 2012-12-27 /pmc/articles/PMC3568736/ /pubmed/23270473 http://dx.doi.org/10.1186/1741-7015-10-172 Text en Copyright ©2012 Sun et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Sun, Qing
Zhong, Yong
Wu, Fan
Zhou, Chunxia
Wang, Dongmei
Ma, Wenbo
Zhang, Youhui
Zhang, Shuren
Immunotherapy using slow-cycling tumor cells prolonged overall survival of tumor-bearing mice
title Immunotherapy using slow-cycling tumor cells prolonged overall survival of tumor-bearing mice
title_full Immunotherapy using slow-cycling tumor cells prolonged overall survival of tumor-bearing mice
title_fullStr Immunotherapy using slow-cycling tumor cells prolonged overall survival of tumor-bearing mice
title_full_unstemmed Immunotherapy using slow-cycling tumor cells prolonged overall survival of tumor-bearing mice
title_short Immunotherapy using slow-cycling tumor cells prolonged overall survival of tumor-bearing mice
title_sort immunotherapy using slow-cycling tumor cells prolonged overall survival of tumor-bearing mice
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3568736/
https://www.ncbi.nlm.nih.gov/pubmed/23270473
http://dx.doi.org/10.1186/1741-7015-10-172
work_keys_str_mv AT sunqing immunotherapyusingslowcyclingtumorcellsprolongedoverallsurvivaloftumorbearingmice
AT zhongyong immunotherapyusingslowcyclingtumorcellsprolongedoverallsurvivaloftumorbearingmice
AT wufan immunotherapyusingslowcyclingtumorcellsprolongedoverallsurvivaloftumorbearingmice
AT zhouchunxia immunotherapyusingslowcyclingtumorcellsprolongedoverallsurvivaloftumorbearingmice
AT wangdongmei immunotherapyusingslowcyclingtumorcellsprolongedoverallsurvivaloftumorbearingmice
AT mawenbo immunotherapyusingslowcyclingtumorcellsprolongedoverallsurvivaloftumorbearingmice
AT zhangyouhui immunotherapyusingslowcyclingtumorcellsprolongedoverallsurvivaloftumorbearingmice
AT zhangshuren immunotherapyusingslowcyclingtumorcellsprolongedoverallsurvivaloftumorbearingmice